Association of plasma macrophage colony-stimulating factor with cardiovascular morbidity and all-cause mortality in chronic hemodialysis patients

• Published in: BMC nephrology Vol. 20; no. 1; p. 321
• Main Authors: Deng, Xuan, Yang, Qian, Wang, Yuxi, Yang, Yi, Pei, Guangchang, Zhu, Han, Wu, Jianliang, Wang, Meng, Zhao, Zhi, Xu, Huzi, Zhou, Cheng, Guo, Yi, Yao, Ying, Zhang, Zhiguo, Liao, Wenhui, Zeng, Rui
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.08.2019; BioMed Central; BMC
• Subjects: All-cause mortality; Atherosclerosis; Cardiovascular diseases; Coronary heart disease; CVD events; Death; Development and progression; Enzyme-linked immunosorbent assay; Health aspects; Hemodialysis; Hemodialysis patients; M-CSF; Macrophage colony stimulating factor; Macrophages; Medical research; Morbidity; Mortality; Patient outcomes; Regression analysis; Thrombosis; China; All-cause mortality; M-CSF; Hemodialysis; CVD events
• ISSN: 1471-2369; 1471-2369
• DOI: 10.1186/s12882-019-1510-z

Cardiovascular disease (CVD) events are the main cause of death in long-term hemodialysis (HD) patients. Macrophage colony- stimulating factor (M-CSF) is actively involved in the formation of atherosclerosis and causes plaque instability, thrombosis and the development of acute coronary syndromes. However, little information is available on the role of M-CSF in HD patients. We aimed to investigate the association between plasma M-CSF levels and CVD events as well as all-cause mortality in patients undergoing long-term HD. Fifty two HD patients and 8 healthy controls were recruited in this study. HD patients were followed up from September 2014 to May 2017. The primary end point was CVD event, the secondary outcome was death from any cause. Patients were divided into two groups with low and high M-CSF levels based on the optimal cut-off value determined by the ROC curve. Cox regression analyses were used to assess the predictive value of plasma M-CSF for CVD events and all-cause mortality in HD patients. We tested the levels of plasma M-CSF and other inflammatory cytokines in surviving HD patients using ELISA or CBA kit. The average plasma level of M-CSF in 52 patients was approximately twice that of healthy controls (992.4 vs. 427.2 pg/mL; p <  0.05). During 32 months of follow-up, 26 patients (50.0%) had at least one CVD event and 8 patients (15.4%) died. The mean plasma M-CSF concentration increased in survivors after follow-up compared to that detected at baseline (1277.8 ± 693.3 vs. 997.2 ± 417.4 pg/mL; p <  0.05). Multivariate Cox regression analysis showed that plasma M-CSF is an independent risk factor for CVD events in HD patients (p <  0.05). In the Cox regression model after adjusting for gender and age, high M-CSF levels were related to an increased risk of all-cause death (p <  0.05). We also found that M-CSF levels were positively correlated with IL-6 and IL-18 levels (both p < 0.05), which are the major pathogentic cytokines that contribute to HD-related CVD events. M-CSF is a prognostic factor for CVD events and all-cause mortality in HD patients.